The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case report

Maharaj, MashaHeslop, LucilleGovender, TrishaKorowlay, NisaarSingh, AviralChoudhary, ParthaSathekge, Mike Machaba2022-02-142021-06Maharaj, M., Heslop, L., Govender, T. et al. The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nuclear Medicine and Molecular Imaging 55, 136–140 (2021). https://doi.org/10.1007/s13139-021-00696-5.1869-3474 (print)1869-3482 (online)10.1007/s13139-021-00696-5http://hdl.handle.net/2263/83831Please read abstract in the article.en© Korean Society of Nuclear Medicine 2021. The original publication is available at : https://link.springer.com/journal/13139.Prostate-specific membrane antigen (PSMA)Lutetium-177 (177Lu)DocetaxelProstate cancerRadiosensitizerRe-challengeRadioligand therapy (RLT)Metastatic castrate-resistant prostate cancer (mCRPC)The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case reportPostprint Article